Astellas has failed to heed warnings about not following the UK pharma industry code, and has only narrowly avoided being expelled from industry membership.
Astellas has been taken to task for breaching the UK pharma industry's self-regulatory Code of Practice during an event convened to discuss its prostate cancer therapy Xtandi in Italy last
A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.